Latest Conference Articles

December 10th 2013, 6:23am

ASH Annual Meeting and Exposition

Jacob Laubach, MD, MPP, from Dana-Farber Cancer Institute, discusses responses observed following the administration of daratumumab for patients with multiple myeloma.

December 9th 2013, 5:09pm

ASH Annual Meeting and Exposition

Ian W. Flinn, MD, PhD, from the Sarah Cannon Research Institute, discusses the preliminary efficacy of IPI-145 in patients with chronic lymphocyic leukemia (CLL).

December 9th 2013, 3:12pm

ASH Annual Meeting and Exposition

The BTK inhibitor ibrutinib rapidly reduced serum immunoglobulin M levels and improved hematocrit levels in patients with relapsed or refractory Waldenström's macroglobulinemia, and the responses to ibrutinib were durable.

December 9th 2013, 3:12pm

ASH Annual Meeting and Exposition

Almost half of patients with relapsed or refractory chronic lymphocytic leukemia attained objective responses when treated with an oral inhibitor of phosphoinositide-3-kinase-delta and -gamma.

December 9th 2013, 9:26am

ASH Annual Meeting and Exposition

ABT-199, an orally bioavailable selective inhibitor of the Bcl-2 protein as monotherapy, induced remissions in patients with relapsed/refractory CLL and SLL, including adverse-risk subsets of patients.

December 9th 2013, 8:20am

ASH Annual Meeting and Exposition

The combination of continuous lenalidomide and low-dose dexamethasone extends PFS and trends toward improving OS compared with the standard MPT in patients with transplant-ineligible newly diagnosed multiple myeloma.

December 9th 2013, 6:02am

ASH Annual Meeting and Exposition

Patients with chronic lymphocytic leukemia and major comorbidities had significantly better outcomes when treated with the anti-CD20 monoclonal antibody obinutuzumab instead of rituximab.

December 8th 2013, 5:55pm

ASH Annual Meeting and Exposition

Treatment with engineered donor T cells led to substantial tumor regression in patients with posttransplant relapsed B-cell malignancies, results of a small clinical study showed.

December 8th 2013, 4:34pm

ASH Annual Meeting and Exposition

Valentin Goede, MD, from the University Hospital Cologne, discusses the efficacy findings from the stage 2 CLL11 study that examined obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia with comorbidities.

December 8th 2013, 11:31am

ASH Annual Meeting and Exposition

Intervention in early or "smoldering" myeloma with a three-drug regimen led to complete responses in a group of high-risk patients, suggesting a window of opportunity that may delay or prevent progression to a debilitating disease state.

December 8th 2013, 11:09am

ASH Annual Meeting and Exposition

A higher cumulative dose of bortezomib, including a longer duration of treatment and/or higher dose intensity, appears to improve OS in patients with previously untreated multiple myeloma.

December 8th 2013, 7:32am

ASH Annual Meeting and Exposition

Jennifer Brown, MD, PhD, from the Dana-Farber Cancer Institute, discusses the development of the novel PI3K-delta inhibitor idelalisib as a treatment for patients with chronic lymphocytic leukemia.

December 8th 2013, 7:30am

ASH Annual Meeting and Exposition

John F. Seymour, MBBS, FRACP, PhD, discusses the efficacy of single-agent ABT-199 (GDC-0199), a novel Bcl-2 inhibitor, in high-risk relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

December 4th 2013, 3:25pm

ASH Annual Meeting and Exposition

To gain insight into the studies being presented at the ASH Annual Meeting, we interviewed Marcel R.M. van den Brink, MD, PhD, on abstracts being presented by faculty at Memorial Sloan-Kettering Cancer Center.

December 4th 2013, 3:02pm

ASH Annual Meeting and Exposition

Marcel R.M. van den Brink, MD, PhD, Head, discusses a trial being presented at the 2013 ASH Annual Meeting, analyzing the addition of ibrutinib to R-CHOP in patients with non-Hodgkin's lymphoma (NHL).

November 26th 2013, 2:23pm

San Antonio Breast Cancer Symposium

Presentations at the 36th San Antonio Breast Cancer Symposium (SABCS) will tackle key topics and questions regarding the treatment of breast cancer.

November 11th 2013, 12:44pm

PER® New York Lung Cancer Symposium

The future of PD-1 and PD-L1 inhibition in non-small cell lung cancer is bright, with ongoing studies suggesting that the strategy will lead to a 'new world' in the treatment of the disease

November 11th 2013, 9:56am

PER® New York Lung Cancer Symposium

Next-generation ALK inhibitors are being developed to address the unmet need of patients with non-small cell lung cancer who are becoming resistant to crizotinib.

November 11th 2013, 7:40am

PER® New York Lung Cancer Symposium

While targeted and immunotherapy drugs have recently shown promise in non-small cell lung cancer (NSCLC), similar developments in small cell lung cancer (SCLC) have not materialized.

November 10th 2013, 10:00am

PER® New York Lung Cancer Symposium

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.